The United States government has finalized a drug pricing agreement with Regeneron, marking the last in a series of deals with major pharmaceutical companies aimed at reducing prescription costs. The policy centres on aligning American drug prices with those paid in other developed countries.
The agreement introduces lower prices for existing treatments and extends pricing rules to future medicines. It also forms part of a broader initiative affecting companies that collectively represent a large share of the branded drug market in the United States.
Regeneron Agreement Expands Pricing Reforms to New Medicines
The deal requires Regeneron to apply “most-favoured-nation” pricing to all new medicines, meaning U.S. patients would pay rates comparable to those in other wealthy nations. According to a White House fact sheet released on 23 April 2026, this provision applies across the company’s full pipeline of experimental treatments, from early-stage trials to late-stage development.
The same document states that Regeneron will reduce the price of its cholesterol drug Praluent from $537 to $225 for patients purchasing through the federal TrumpRx platform. This website, launched earlier in 2026, is designed to provide direct access to discounted brand-name medicines.
The agreement also includes provisions affecting public healthcare programmes. According to the White House, all state Medicaid programmes will gain access to these lower prices for new Regeneron drugs, with projected savings reaching hundreds of millions of dollars.
Reuters reports that the deal completes a set of agreements with 17 pharmaceutical manufacturers, collectively accounting for 86% of the branded drug market in the United States. These companies have committed to similar pricing structures as part of negotiations tied to trade and tariff policies.
Broad pipeline of treatments affected across multiple diseases
Regeneron’s development portfolio spans a wide range of therapies across Phase 1, Phase 2 and Phase 3 clinical trials, all of which fall within the scope of the new pricing framework. According to the White House fact sheet and company pipeline data cited in the announcement, these treatments include:
Phase 1 clinical trials:
- 27T51 – immune cell therapy for ovarian cancers
- ALN-5288 – gene silencing therapy for Alzheimer’s disease
- ALN-APOC3 – gene silencing therapy for dyslipidaemia
- ALN-CFB – gene silencing therapy for paroxysmal nocturnal haemoglobinuria
- ALN-CIDEB – gene silencing therapy for metabolic dysfunction-associated steatohepatitis
- ALN-F1202 – experimental therapy in healthy participants
- ALN-HTT02 – gene silencing therapy for Huntington’s disease
- ALN-PNP – gene silencing therapy for metabolic dysfunction-associated steatotic liver disease
- ALN-SNCA – gene silencing therapy for Parkinson’s disease
- ALN-SOD – gene silencing therapy for amyotrophic lateral sclerosis
- DUPILUMAB / LINVOSELTAMAB – treatment for severe IgE-mediated food allergy
- NEZASTOMIG (REGN5678) – antibody for renal cell carcinoma
- NEZASTOMIG / CEMIPLIMAB – antibody combination for prostate and renal cancers
- NEZASTOMIG / REGN4336 – antibody for prostate cancer
- REGN5837 – antibody for B-cell non-Hodgkin lymphomas
- REGN7041 – antibody for non-infectious uveitis
- REGN7945 – antibody for multiple myeloma
- REGN9533 – experimental antibody in healthy participants
- REGN10597 – antibody for solid tumours
- REGN13335 – experimental antibody in healthy participants
- REGV131-LNP1265 – gene editing therapy for haemophilia B
- VONSETAMIG (REGN5459) – antibody for transplant desensitisation
Phase 2 clinical trials:
- ALN-ANG3 – gene silencing therapy for diabetic kidney disease
- CEMIPLIMAB – antibody for cutaneous squamous cell carcinoma
- DAVUTAMIG (REGN5093) – antibody for non-small cell lung cancer
- DB-OTO – gene therapy for genetic hearing loss
- FIANLIMAB – antibody for advanced lung cancer
- ITEPEKIMAB – antibody for chronic rhinosinusitis
- LINVOSELTAMAB – antibody for multiple myeloma
- MARLOTAMIG (REGN7075) – antibody for solid tumours
- MIBAVADEMAB – antibody for functional hypothalamic amenorrhoea
- NEZASTOMIG (REGN5678) – antibody for prostate cancer
- ODRONEXTAMAB – antibody for B-cell non-Hodgkin lymphoma
- RAPIROSIRAN (ALN-HSD) – gene silencing therapy for MASH
- REGN5668 – antibody for ovarian cancer
- REGN7508 – antibody for thrombosis
- REGN7544 – antibody for POTS and sepsis-induced hypotension
- REGN7999 – antibody for beta-thalassaemia
- REGN9933 – antibody for thrombosis
- SARILUMAB – antibody for systemic juvenile idiopathic arthritis
- TREVOGRUMAB (REGN1033) – antibody for obesity
- UBAMATAMAB (REGN4018) – antibody for ovarian cancer
Phase 3 clinical trials:
- CEMDISIRAN – gene silencing therapy for myasthenia gravis
- CEMIPLIMAB – antibody for early-stage cutaneous squamous cell carcinoma
- DUPILUMAB – antibody for paediatric asthma
- FIANLIMAB – antibody for metastatic melanoma
- GARETOSMAB – antibody for fibrodysplasia ossificans progressiva
- ITEPEKIMAB – antibody for chronic obstructive pulmonary disease
- LINVOSELTAMAB – antibody for multiple myeloma
- MIBAVADEMAB – antibody for generalised lipodystrophy
- NEXIGURAN ZICLUMERAN (NTLA-2001) – gene editing therapy for transthyretin amyloidosis
- ODRONEXTAMAB – antibody for follicular lymphoma
- POZELIMAB + CEMDISIRAN – gene silencing therapy for myasthenia gravis and PNH
- REGN1908-1909 – antibody for cat allergy
- REGN5713-5715 – antibody for birch allergy
- REGN7508 – antibody for venous thromboembolism
The agreement coincides with the approval of Otarmeni, a gene therapy for a rare form of genetic hearing loss in children, which will be provided at no cost in the United States, according to Reuters and the White House. The company has also committed to investing $27 billion in domestic research, development and manufacturing by 2029.
The Regeneron deal completes a broader set of agreements with 17 pharmaceutical companies, including Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Amgen, Merck and Johnson & Johnson, all of which have joined the TrumpRx platform under similar pricing terms, according to the White House.
Enjoyed this article? Subscribe to our free Newsletter for engaging stories, exclusive content, and the latest news.
